Exagen Inc.

clinical laboratory company

XGN Nasdaq ISIN US30068X1037 SEC CIK 1274737
Follow Exagen Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $18.4M +6.8% vs same quarter last year
Net income −$6.3M +10.6% vs same quarter last year
EPS, diluted −$0.25 +19.4% vs same quarter last year
Operating cash flow −$2.6M −187.5% vs same quarter last year
Revenue by quarter
$13.7M
$15.5M
$17.2M
$17.2M
$16.6M
$17.3M
$19.9M
$18.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$50M$0$50M$100MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$66.6M−$20M
FY24$55.6M−$15.1M
FY23$52.5M−$23.7M
FY22$45.6M−$47.4M
FY21$48.3M−$26.9M
FY20$42M−$16.7M
FY19$40.4M−$12M
FY18$32.4M−$8M
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−150%−100%−50%0%50%100%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2558.3%−21.1%−30%
FY2459.5%−24.5%−27.2%
FY2356.1%−43.5%−45.1%
FY2246.9%−101.1%−104%
FY2157.4%−49.8%−55.6%
FY2060.6%−36.2%−39.8%
FY1953.4%−23%−29.8%
FY1852.6%−15%−24.7%
FY17---
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$14.3M
FY24−$13.8M
FY23−$15.3M
FY22−$36.5M
FY21−$22.6M
FY20−$14.5M
FY19−$10.1M
FY18−$9.5M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Exagen
  • Healthcare median
−150%−100%−50%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearExagenHealthcare median
FY25−30%−30.6%
FY24−27.2%−47%
FY23−45.1%−58%
FY22−104%−80.4%
FY21−55.6%−71.8%
FY20−39.8%−62.2%
FY19−29.8%−46.2%
FY18−24.7%−49.6%
FY17-−45.9%